Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

HCGInterpret the evidence

Why one hCG trigger comparison cannot answer every fertility question

3 numbered sourcesSource years 2023, 2026

Peptides are short chains of amino acids linked by peptide bonds, and some relay signals between organs. Human chorionic gonadotropin (hCG) is a larger, sugar-bearing hormone formed from two amino-acid chains. In some fertility procedures, it supplies a signal that helps eggs finish maturing. A January 2026 trial compared hCG alone with a two-part trigger in women aged 35 to 42. [1, 2]

The study randomized 164 patients undergoing intracytoplasmic sperm injection. One group received an hCG trigger. The other group received a dual trigger containing hCG and a gonadotropin-releasing hormone agonist, which can stimulate a release of pituitary hormones. The research team counted retrieved eggs that had reached metaphase II, the mature stage needed for the fertilization procedure. They also tracked outcomes at later steps and examined what happened in follicles of different sizes. [1]

The main comparison showed similar average numbers of mature eggs in the two groups. Fertilization rates were similar overall, and the observed ongoing pregnancy and live-birth rates did not differ clearly. The analysis by follicle size suggested a higher fertilization rate for eggs from smaller follicles in the dual-trigger group. That was a narrower finding within the trial. It could inform a future study designed around smaller follicles, where the researchers could specify in advance how they would examine that result. [1]

A different 2026 randomized trial reported more mature eggs with a dual trigger among patients selected for both endometriosis and poor ovarian response. This does not make either trial a universal answer. Age, ovarian response and underlying diagnosis are different ways of selecting a population. Both trials examined mature eggs, but an effect detected in one population may be smaller, absent or more uncertain in another. Trial design, sample size and the details of the intervention also influence a comparison. [1, 3]

The approved U.S. prescribing information for recombinant hCG describes specified fertility indications. These studies examined whether adding another signal changed outcomes in particular populations. The question about the number of mature eggs is also distinct from the question about live births. A comparison that finds a change at one step in fertility treatment needs evidence on the later step before it can establish a difference there. [1, 2, 3]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop HCG

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.